Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Coreg Clear all
Completed Phase 3 Interventional Results available

COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

NCT00273052
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol Phosphate modified release formulation, metoprolol succinate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

NCT00508365
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR capsules, Placebo, Lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Anniston, Alabama • Glendale, Arizona • Anaheim, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 10, 2026, 10:58 PM EDT
Terminated Phase 4 Interventional Results available

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

NCT00430040
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Carvedilol Controlled Release (CR), lisinopril
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00108082
View directory record Official record
Conditions
Hypertrophy, Left Ventricular
Interventions
carvedilol MR, atenolol, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

NCT00964678
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Carvedilol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure

NCT00537043
View directory record Official record
Conditions
Hypertension
Interventions
SK&F-105517 (COREG CR FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2010 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00650416
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 10, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Carvedilol in Treating Hypoglycemia Unawareness

NCT03538015
View directory record Official record
Conditions
Hypoglycemia Unawareness
Interventions
Carvedilol 3.125 mg, Carvedilol 2.5 mg, Placebo capsule
Drug
Lead sponsor
Owen Chan, PhD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

NCT00052026
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol, placebo
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2008 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 3 Interventional

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

NCT00272805
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
carvedilol
Drug
Lead sponsor
Cardiovascular Clinical Sciences Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
54
States / cities
Mobile, Alabama • Sierra Vista, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects

NCT00834795
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol 25 mg tablets, COREG® 25 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

NCT00657241
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Valsartan
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 10, 2026, 10:58 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components

NCT00556920
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 10, 2026, 10:58 PM EDT
Not listed Phase 2 Interventional

Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate

NCT02944201
View directory record Official record
Conditions
Prostate Cancer
Interventions
Carvedilol
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 10, 2026, 10:58 PM EDT
Terminated Phase 4 Interventional

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

NCT00433043
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Beta blocker (carvedilol or metoprolol succinate), CRT (cardiac resynchronization therapy)
Drug · Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 10, 2026, 10:58 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

"The Evaluation of Stimulant Withdrawal"

NCT00442923
View directory record Official record
Conditions
Anxiety, Relapse, Substance Addiction
Interventions
Coreg
Drug
Lead sponsor
Aaron J. Janowsky
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

NCT00123604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Carvedilol, Metoprolol
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 10, 2026, 10:58 PM EDT
Not listed Phase 2 Interventional

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

NCT01221792
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Diego, California • Lake Charles, Louisiana • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol on Exercise Performance in Fontan Patients

NCT02946892
View directory record Official record
Conditions
Single Ventricle, Fontan
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 4 Interventional

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

NCT01261065
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy
Interventions
carvedilol
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 10, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00557128
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 10, 2026, 10:58 PM EDT